November 3, 2015 / 1:13 PM / 2 years ago

BRIEF-Bavarian Nordic: MVA-BN based vaccine proved can induce brachyury-specific T-cell immune responses

Nov 3 (Reuters) - Bavarian Nordic A/S

* Announces results of a Phase 1 trial investigating brachyury specific cancer vaccine in patients with advanced cancers

* Data from this study demonstrate for the first time that an MVA-BN based vaccine targeting brachyury can induce brachyury-specific T-cell immune responses in advanced cancer patients

* Vaccine induced brachyury specific T-cells in 80 pct of patients at higher dose levels

* MVA-BN brachyury was well tolerated with no dose limiting toxicities

* Maximal tolerated dose was not reached

* No serious adverse vaccine-related events were observed

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below